Evaluation of MUC1, MUC2, MUC5AC, and MUC6 Expression Differences in Lung Adenocarcinoma Subtypes by Using a Final Immunoreactivity Score (FIRS)

firat, pinar; Buyuk, Melek; Ozluk, Yasemin; Vurallı Bakkaloglu, Dogu; Ozkan, Berker; YILMAZBAYHAN, EMINE DILEK

doi:10.5146/tjpath.2022.01593

Evaluation of MUC1, MUC2, MUC5AC, and MUC6 Expression Differences in Lung Adenocarcinoma Subtypes by Using a Final Immunoreactivity Score (FIRS)

Melek BÜYÜK, (İstanbul Üniversitesi, Tıp Fakültesi, Patoloji Anabilim Dalı, İstanbul, Türkiye)

Yasemin ÖZLÜK, (İstanbul Üniversitesi, Tıp Fakültesi, Patoloji Anabilim Dalı, İstanbul, Türkiye)

Dogu VURALLI BAKKALOGLU, (İstanbul Üniversitesi, Tıp Fakültesi, Patoloji Anabilim Dalı, İstanbul, Türkiye)

Berker ÖZKAN, (İstanbul Üniversitesi, Tıp Fakültesi, Göğüs Cerrahisi Anabilim Dalı, İstanbul, Türkiye)

Pınar FIRAT, (Koç Üniversitesi, Tıp Fakültesi, Patoloji Anabilim Dalı, İstanbul, Türkiye)

Dilek YILMAZBAYHAN (İstanbul Üniversitesi, Tıp Fakültesi, Patoloji Anabilim Dalı, İstanbul, Türkiye)

Türk Patoloji Dergisi

2 0

Yıl: 2023 Cilt: 39 Sayı: 1 Sayfa Aralığı: 64 - 74 Metin Dili: İngilizce DOI: 10.5146/tjpath.2022.01593 İndeks Tarihi: 15-05-2023

Evaluation of MUC1, MUC2, MUC5AC, and MUC6 Expression Differences in Lung Adenocarcinoma Subtypes by Using a Final Immunoreactivity Score (FIRS)

Öz:

Objective: Lung adenocarcinomas are divided into acinar, lepidic, papillary, micropapillary, and solid predominant subtypes according to the current World Health Organization (WHO) classification. We designed this retrospective study to demonstrate profiles of MUC expression (MUC1, MUC2, MUC5AC, and MUC6) of different histologic patterns within the same tumor among pulmonary adenocarcinomas and investigate correlations of MUC expression with clinicopathologic features. Material and Method: We analyzed the expression of mucins (MUC1, MUC2, MUC5AC, and MUC6) in a series of 99 resected lung adenocarcinomas, which included a total of 193 patterns (71 acinar, 30 lepidic, 25 papillary, 20 micropapillary, 34 solid and 13 mucinous) and calculated a final immune reactivity score (FIRS) per tumor. Results: MUC1 IRS scores were significantly higher in lepidic and solid patterns compared with mucinous patterns (p=0.013). MUC2 expression was seen only in three cases (1 acinar, 2 mucinous). MUC5AC and MUC2 expression was more common in mucinous patterns (p<0.001 and p=0.028, respectively). MUC6 expression was only detected in seven patterns and the expression was weak. No significant difference was seen among histologic patterns for the staining scores of MUC6. Mucinous adenocarcinoma differed from other histologic subtypes regarding MUC1 and MUC5AC expression. Mucinous adenocarcinoma showed less MUC1 expression with lower IRS scores and higher MUC5AC expression. Tumor size (p=0.006), lymphatic invasion (p=0.018), vascular invasion (p=0.025), perineural invasion (p=0.019), MUC1 IRS scores (p=0.018), and MUC1 IRS scores >8.5 (p=0.018) were significant predictors for lymph node metastasis. Conclusion: An alternative scoring for MUC1 can be used as a predictor for lymph node metastasis regardless of the histologic subtype.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Rose MC, Voynow JA. Respiratory tract mucin genes and mucin glycoproteins in health and disease. Physiol Rev 2006;86:245-78.
2. Evans CM, Koo JS. Airway mucus: The good, the bad, the sticky. Pharmacol Ther 2009;121:332-48.
3. Hollingsworth MA, Swanson BJ. Mucins in cancer: Protection and control of the cell surface. Nat Rev Cancer 2004;4:45-60.
4. Ho SB, Niehans GA, Lyftogt C, Yan PS, Cherwitz DL, Gum ET, Dahiya R, Kim YS. Heterogeneity of mucin gene expression in normal and neoplastic tissues. Cancer Res. 1993;53:641-51.
5. Chambers JA, Hollingsworth MA, Trezise AE, Harris A. Developmental expression of mucin genes MUC1 and MUC2. J Cell Sci. 1994;107:413-24.
6. Ho SB, Shekels LL, Toribara NW, Kim YS, Lyftogt C, Cherwitz DL, Niehans GA. Mucin gene expression in normal, preneoplastic, and neoplastic human gastric epithelium. Cancer Res. 1995;55:2681-90.
7. Nguyen PL, Niehans GA, Cherwitz DL, Kim YS, Ho SB. Membrane-bound (MUC1) and secretory (MUC2, MUC3, and MUC4) mucin gene expression in human lung cancer. Tumour Biol. 1996;7:176-92.
8. Wesseling J, van der Valk SW, Hilkens J. A mechanism for inhibition of E-cadherin-mediated cell-cell adhesion by the membrane-associated mucin episialin/MUC1. Mol Biol Cell. 1996;7:565-77.
9. Wesseling J, van der Valk SW, Vos HL, Sonnenberg A, Hilkens J. Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components. J Cell Biol. 1995; 129:255-65.
10. van de Wiel-van Kemenade E, Ligtenberg MJ, de Boer AJ, Buijs F, Vos HL, Melief CJ, Hilkens J, Figdor CG. Episialin (MUC1) inhibits cytotoxic lymphocyte-target cell interaction. J Immunol. 1993;151:767-76.
11. McGuckin MA, Walsh MD, Hohn BG, Ward BG, Wright RG. Prognostic significance of MUC1 epithelial mucin expression in breast cancer. Hum Pathol. 1995;26:432-9.
12. Taverna C, Maggiore G, Cannavicci A, Bonomo P, Santucci M, Franchi A. Immunohistochemical profiling of mucins in sinonasal adenocarcinomas. Pathol Res Pract. 2019;215:152439.
13. Wang XT, Kong FB, Mai W, Li L, Pang LM. MUC1 Immunohistochemical Expression as a Prognostic Factor in Gastric Cancer: Meta-Analysis. Dis Markers. 2016;2016:9421571.
14. Hinoda Y, Ikematsu Y, Horinochi M, Sato S, Yamamoto K, Nakano T, Fukui M, Suehiro Y, Hamanaka Y, Nishikawa Y, Kida H, Waki S, Oka M, Imai K, Yonezawa S. Increased expression of MUC1 in advanced pancreatic cancer. J Gastroenterol. 2003;38:1162-6.
15. WHO Classification of tumors editorial board. Thoracic Tumors. Lyon (France): International Agency for Cancer Research on Cancer; 2021 (WHO classification of tumors series, 5th edition. Volume: 52021.
16. Woenckhaus M, Merk J, Stoehr R, Schaeper F, Gaumann A, Wiebe K, Hartmann A, Hofstaedter F, Dietmaier W. Prognostic value of FHIT, CTNNB1, and MUC1 expression in non-small cell lung cancer. Hum Pathol. 2008;39:126-36.
17. Situ D, Wang J, Ma Y, Zhu Z, Hu Y, Long H, Rong T. Expression and prognostic relevance of MUC1 in stage IB non-small cell lung cancer. Med Oncol. 2011;28 Suppl 1:S596-604.
18. Nagai S, Takenaka K, Sonobe M, Ogawa E, Wada H, Tanaka F. A novel classification of MUC1 expression is correlated with tumor differentiation and postoperative prognosis in non-small cell lung cancer. J Thorac Oncol. 2006;1:46-51.
19. Guddo F, Giatromanolaki A, Patriarca C, Hilkens J, Reina C, Alfano RM, Vignola AM, Koukourakis MI, Gambacorta M, Pruneri G, Coggi G, Bonsignore G. Depolarized expression of episialin (EMA, MUC1) in lung adenocarcinoma is associated with tumor progression. Anticancer Res. 1998;18:1915-20.
20. Tsutsumida H, Goto M, Kitajima S, Kubota I, Hirotsu Y, Yonezawa S. Combined status of MUC1 mucin and surfactant apoprotein A expression can predict the outcome of patients with small-size lung adenocarcinoma. Histopathology. 2004;44:147- 55.
21. Palmer M, Parker J, Modi S, Butts C, Smylie M, Meikle A, Kehoe M, MacLean G, Longenecker M. Phase I study of the BLP25 (MUC1 peptide) liposomal vaccine for active specific immunotherapy in stage IIIB/IV non-small-cell lung cancer. Clin Lung Cancer. 2001;3:49-57; discussion 58.
22. Butts C, Murray N, Maksymiuk A, Goss G, Marshall E, Soulieres D, Cormier Y, Ellis P, Price A, Sawhney R, Davis M, Mansi J, Smith C, Vergidis D, Ellis P, MacNeil M, Palmer M. Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J Clin Oncol. 2005;23:6674-81.
23. Duruisseaux M, Antoine M, Rabbe N, Rodenas A, Mc Leer-Florin A, Lacave R, Poulot V, Duchene B, Van Seuningen I, Cadranel J, Wislez M. Lepidic predominant adenocarcinoma and invasive mucinous adenocarcinoma of the lung exhibit specific mucin expression in relation with oncogenic drivers. Lung Cancer. 2017;109:92-100.
24. Tsuta K, Ishii G, Nitadori J, Murata Y, Kodama T, Nagai K, Ochiai A. Comparison of the immunophenotypes of signet-ring cell carcinoma, solid adenocarcinoma with mucin production, and mucinous bronchioloalveolar carcinoma of the lung characterized by the presence of cytoplasmic mucin. J Pathol. 2006;209:78-87.
25. Rossi G, Murer B, Cavazza A, Losi L, Natali P, Marchioni A, Migaldi M, Capitanio G, Brambilla E. Primary mucinous (so- called colloid) carcinomas of the lung: A clinicopathologic and immunohistochemical study with special reference to CDX- 2 homeobox gene and MUC2 expression. Am J Surg Pathol. 2004;28:442-52.
26. Awaya H, Takeshima Y, Yamasaki M, Inai K. Expression of MUC1, MUC2, MUC5AC, and MUC6 in atypical adenomatous hyperplasia, bronchioloalveolar carcinoma, adenocarcinoma with mixed subtypes, and mucinous bronchioloalveolar carcinoma of the lung. Am J Clin Pathol. 2004;121:644-53.
27. Copin MC, Buisine MP, Leteurtre E, Marquette CH, Porte H, Aubert JP, Gosselin B, Porchet N. Mucinous bronchioloalveolar carcinomas display a specific pattern of mucin gene expression among primary lung adenocarcinomas. Hum Pathol. 2001;32:274-81.
28. Remmele W, Stegner HE. Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe. 1987;8:138-40.
29. Guddo F, Giatromanolaki A, Koukourakis MI, Reina C, Vignola AM, Chlouverakis G, Hilkens J, Gatter KC, Harris AL, Bonsignore G. MUC1 (episialin) expression in non-small cell lung cancer is independent of EGFR and c-erbB-2 expression and correlates with poor survival in node positive patients. J Clin Pathol. 1998; 51:667-71.

APA	Buyuk M, Ozluk Y, Vurallı Bakkaloglu D, Ozkan B, firat p, YILMAZBAYHAN E (2023). Evaluation of MUC1, MUC2, MUC5AC, and MUC6 Expression Differences in Lung Adenocarcinoma Subtypes by Using a Final Immunoreactivity Score (FIRS). , 64 - 74. 10.5146/tjpath.2022.01593
Chicago	Buyuk Melek,Ozluk Yasemin,Vurallı Bakkaloglu Dogu,Ozkan Berker,firat pinar,YILMAZBAYHAN EMINE DILEK Evaluation of MUC1, MUC2, MUC5AC, and MUC6 Expression Differences in Lung Adenocarcinoma Subtypes by Using a Final Immunoreactivity Score (FIRS). (2023): 64 - 74. 10.5146/tjpath.2022.01593
MLA	Buyuk Melek,Ozluk Yasemin,Vurallı Bakkaloglu Dogu,Ozkan Berker,firat pinar,YILMAZBAYHAN EMINE DILEK Evaluation of MUC1, MUC2, MUC5AC, and MUC6 Expression Differences in Lung Adenocarcinoma Subtypes by Using a Final Immunoreactivity Score (FIRS). , 2023, ss.64 - 74. 10.5146/tjpath.2022.01593
AMA	Buyuk M,Ozluk Y,Vurallı Bakkaloglu D,Ozkan B,firat p,YILMAZBAYHAN E Evaluation of MUC1, MUC2, MUC5AC, and MUC6 Expression Differences in Lung Adenocarcinoma Subtypes by Using a Final Immunoreactivity Score (FIRS). . 2023; 64 - 74. 10.5146/tjpath.2022.01593
Vancouver	Buyuk M,Ozluk Y,Vurallı Bakkaloglu D,Ozkan B,firat p,YILMAZBAYHAN E Evaluation of MUC1, MUC2, MUC5AC, and MUC6 Expression Differences in Lung Adenocarcinoma Subtypes by Using a Final Immunoreactivity Score (FIRS). . 2023; 64 - 74. 10.5146/tjpath.2022.01593
IEEE	Buyuk M,Ozluk Y,Vurallı Bakkaloglu D,Ozkan B,firat p,YILMAZBAYHAN E "Evaluation of MUC1, MUC2, MUC5AC, and MUC6 Expression Differences in Lung Adenocarcinoma Subtypes by Using a Final Immunoreactivity Score (FIRS)." , ss.64 - 74, 2023. 10.5146/tjpath.2022.01593
ISNAD	Buyuk, Melek vd. "Evaluation of MUC1, MUC2, MUC5AC, and MUC6 Expression Differences in Lung Adenocarcinoma Subtypes by Using a Final Immunoreactivity Score (FIRS)". (2023), 64-74. https://doi.org/10.5146/tjpath.2022.01593

APA	Buyuk M, Ozluk Y, Vurallı Bakkaloglu D, Ozkan B, firat p, YILMAZBAYHAN E (2023). Evaluation of MUC1, MUC2, MUC5AC, and MUC6 Expression Differences in Lung Adenocarcinoma Subtypes by Using a Final Immunoreactivity Score (FIRS). Türk Patoloji Dergisi, 39(1), 64 - 74. 10.5146/tjpath.2022.01593
Chicago	Buyuk Melek,Ozluk Yasemin,Vurallı Bakkaloglu Dogu,Ozkan Berker,firat pinar,YILMAZBAYHAN EMINE DILEK Evaluation of MUC1, MUC2, MUC5AC, and MUC6 Expression Differences in Lung Adenocarcinoma Subtypes by Using a Final Immunoreactivity Score (FIRS). Türk Patoloji Dergisi 39, no.1 (2023): 64 - 74. 10.5146/tjpath.2022.01593
MLA	Buyuk Melek,Ozluk Yasemin,Vurallı Bakkaloglu Dogu,Ozkan Berker,firat pinar,YILMAZBAYHAN EMINE DILEK Evaluation of MUC1, MUC2, MUC5AC, and MUC6 Expression Differences in Lung Adenocarcinoma Subtypes by Using a Final Immunoreactivity Score (FIRS). Türk Patoloji Dergisi, vol.39, no.1, 2023, ss.64 - 74. 10.5146/tjpath.2022.01593
AMA	Buyuk M,Ozluk Y,Vurallı Bakkaloglu D,Ozkan B,firat p,YILMAZBAYHAN E Evaluation of MUC1, MUC2, MUC5AC, and MUC6 Expression Differences in Lung Adenocarcinoma Subtypes by Using a Final Immunoreactivity Score (FIRS). Türk Patoloji Dergisi. 2023; 39(1): 64 - 74. 10.5146/tjpath.2022.01593
Vancouver	Buyuk M,Ozluk Y,Vurallı Bakkaloglu D,Ozkan B,firat p,YILMAZBAYHAN E Evaluation of MUC1, MUC2, MUC5AC, and MUC6 Expression Differences in Lung Adenocarcinoma Subtypes by Using a Final Immunoreactivity Score (FIRS). Türk Patoloji Dergisi. 2023; 39(1): 64 - 74. 10.5146/tjpath.2022.01593
IEEE	Buyuk M,Ozluk Y,Vurallı Bakkaloglu D,Ozkan B,firat p,YILMAZBAYHAN E "Evaluation of MUC1, MUC2, MUC5AC, and MUC6 Expression Differences in Lung Adenocarcinoma Subtypes by Using a Final Immunoreactivity Score (FIRS)." Türk Patoloji Dergisi, 39, ss.64 - 74, 2023. 10.5146/tjpath.2022.01593
ISNAD	Buyuk, Melek vd. "Evaluation of MUC1, MUC2, MUC5AC, and MUC6 Expression Differences in Lung Adenocarcinoma Subtypes by Using a Final Immunoreactivity Score (FIRS)". Türk Patoloji Dergisi 39/1 (2023), 64-74. https://doi.org/10.5146/tjpath.2022.01593